The HSD3B1 gene could hold clues for predicting and treating endometrial cancer, according to a novel finding. Researchers found a certain HSD3B1 genotype was more common in women with type 2 endometrial cancer. Those patients show lower survival rates than those diagnosed with type 1 endometrial cancer, likely driven by the fact that type 2 patient cells are less hormone-dependent.
